Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | completed | Phase 3 | 505 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Feb 5, 2026 | clinicaltrials |
| NCT04776148 | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | completed | Phase 3 | 563 | Merck Sharp & Dohme LLC |
| 15 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | completed | Phase 3 | 804 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 4, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT06240741 | A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan | completed | Phase 3 | 71 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT05061823 | Bintrafusp Alfa Program Rollover Study | completed | Phase 3 | 22 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT05177484 | Perioperative Iron for Colorectal Cancer (PICoC Study)(PICoC) | completed | Phase 3 | 40 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06057168 | Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas(GDX-44-016) | completed | Phase 3 | 138 | GuerbetINDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT01730937 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | completed | Phase 3 | 193 | Radiation Therapy Oncology GroupNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03284866 | HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV(COVENANT) | completed | Phase 3 | 536 | AIDS Malignancy ConsortiumNETWORK | 5 | Jan 28, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT04334759 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma(DREAM3R) | completed | Phase 3 | 214 | PrECOG, LLC.OTHER | 3 | Jan 22, 2026 | clinicaltrials |
| NCT03377491 | Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | completed | Phase 3 | 571 | NovoCure Ltd.INDUSTRY | 20 | Jan 21, 2026 | clinicaltrials |
| NCT04457297 | Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection(ALTAIR) | completed | Phase 3 | 243 | National Cancer Center Hospital EastOTHER | 2 | Jan 21, 2026 | clinicaltrials |
| NCT05153785 | Perioperative Intravenous Lidocaine in Liver Surgery | completed | Phase 2 / Phase 3 | 124 | Lund University HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT01413269 | Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery | completed | Phase 3 | 720 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT01856478 | LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 340 | Boehringer IngelheimINDUSTRY | 8 | Jan 12, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03474107 | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | completed | Phase 3 | 608 | Astellas Pharma Global Development, Inc.INDUSTRY | 19 | Jan 9, 2026 | clinicaltrials |
| NCT06058793 | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 3 | 138 | Boehringer IngelheimINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT04655144 | Dexamethasone for Post Uterine Artery Embolization Pain(Dex-Fib) | completed | Phase 3 | 42 | University of MiamiOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT07320950 | Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients | completed | Phase 3 | 333 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | completed | Phase 3 | 236 | Radiation Therapy Oncology GroupNETWORK | 4 | Dec 31, 2025 | clinicaltrials |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer(S1216) | completed | Phase 3 | 1,313 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00133887 | TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients | completed | Phase 3 | 77 | Hospices Civils de LyonOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT00757302 | Intraoperative Gamma Camera for Breast Cancer Surgery | completed | Phase 3 | 110 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT00799188 | CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial(CERTICOEUR) | completed | Phase 3 | 175 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT03009981 | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | completed | Phase 3 | 504 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT05114720 | Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | completed | Phase 3 | 559 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02926196 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab(A-Brave) | completed | Phase 3 | 474 | Istituto Oncologico Veneto IRCCSOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials